Edition:
United States

Neovacs SA (ALNEV.PA)

ALNEV.PA on Paris Stock Exchange

0.83EUR
28 Apr 2017
Change (% chg)

€-0.01 (-1.19%)
Prev Close
€0.84
Open
€0.84
Day's High
€0.84
Day's Low
€0.81
Volume
126,360
Avg. Vol
718,737
52-wk High
€1.33
52-wk Low
€0.66

ALNEV.PA

Chart for ALNEV.PA

About

Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company... (more)

Overall

Beta: 0.54
Market Cap(Mil.): €35.66
Shares Outstanding(Mil.): 42.97
Dividend: --
Yield (%): --

Financials

  ALNEV.PA Industry Sector
P/E (TTM): -- 58.40 30.08
EPS (TTM): -0.16 -- --
ROI: -100.09 -0.42 13.25
ROE: -181.68 5.87 14.41

BRIEF-Neovacs FY operating loss widens to 17.3‍​ million euros

* FY revenue ‍​0.4 million euros versus 1.2 million euros ($1.29 million) year ago

Mar 30 2017

BRIEF-Neovacs and Biosense sign option agreement worth up to €65 million plus royalties

* Neovacs and Biosense sign option agreement worth up to €65 million plus royalties for Chinese development and commercial rights to ifnα kinoid for lupus and dermatomyositis

Feb 21 2017

BRIEF-Neovacs and Biosense sign option agreement worth up to 65 million euros

* And biosense sign option agreement worth up to 65 million euros ($68.80 million) plus royalties for Chinese development and commercial rights to Ifnalpha Kinoid for lupus and dermatomyositis

Feb 21 2017

BRIEF-Neovacs issued new broad patent in China for IFNalpha Kinoid

* Announced today that it has received notification of a new patent from the Chinese patent office

Feb 09 2017

BRIEF-Neovacs presents first positive immunogenicity results for IFN kinoid in diabetes of type 1

* Neovacs presents first positive immunogenicity results for IFN kinoid in diabetes of type 1

Jan 25 2017

BRIEF-Neovacs signs production partnership with 3P Biopharmaceuticals

* Neovacs signs production partnership with 3p biopharmaceuticals, a leading gmp producer of biological drugs Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 23 2016

BRIEF-Neovacs acquires Interferon Alpha manufacturing technology

* Acquires interferon alpha manufacturing technology from AMEGABIOTECH Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 15 2016

BRIEF-Neovacs enrolls first US patient in phase IIb study of IFNa Kinoid for SLE treatment

* Neovacs enrolls the first US patient in phase IIb study of IFNa Kinoid for treatment of Systemic Lupus Erythematosus (SLE) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 07 2016

More From Around the Web

Earnings vs. Estimates